Has Chan Chen, MD received payments from drug or device companies?

Yes. Drug and device makers reported $899 in general payments to Chan Chen, MD across 22 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Chan Chen, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Chan Chen, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Chan Chen, MD

Neurology · Plainsboro, NJNPI 1619322575

Payments from drug & device makers

$899in general payments, 2019–2025

Across 22 payments — averaging $40.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Argenx US, Inc.$264
Dexcom, Inc.$124
AstraZeneca$123
Novo Nordisk$118
E.r. Squibb & Sons, L.L.C.$110
Bristol Myers Squibb$69
plus $91 from 4 others

What the payments were for

Food & beverage$899100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Argenx US, Inc.	9	$264
Dexcom, Inc.	1	$124
AstraZeneca	1	$123
Novo Nordisk	1	$118
E.r. Squibb & Sons, L.L.C.	1	$110
Bristol Myers Squibb	4	$69
UCB, Inc.	2	$42
Bayer	1	$20
Genentech USA, Inc.	1	$16
Melinta Therapeutics, LLC	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$899 in reported general payments places this provider in the 35th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey →

Medicare billing

Part B allowed, 2024

$21,047

Medicare patients

Services billed

169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Gabapentin	37	$644
Levetiracetam	26	$445
Cyclobenzaprine Hcl	15	$218

Paid to pharmacies, not to this prescriber.

Other neurology in Plainsboro

Mary Ann PiconeTeaneck$2.8M
Steven BromleyAudubon$1.7M
David DuncanNeptune$1.5M
Lana Zhovtis RyersonNeptune$1.3M
Amos KatzEatontown$1.2M
Fiona GuptaOradell$1.1M
Andrew SylvesterBridgewater$1.1M
Machteld HillenNewark$999K
Matthew TremblayLivingston$812K
Noah GilsonWest Long Branch$800K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →